Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) Bundle
A Brief History of Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd., a key player in China's pharmaceutical sector, was founded in 1996. The company specializes in manufacturing traditional Chinese medicine and chemical pharmaceuticals.
In 2001, Tonghua Golden-Horse was listed on the Shenzhen Stock Exchange under the ticker symbol 002750. This listing provided significant capital for expansion and R&D initiatives.
By 2010, the company's revenue exceeded 1 billion RMB, indicating a rapid growth trajectory fueled by an expanding product portfolio and an increasing market demand for healthcare products. The net profit margin that year reached approximately 20%.
In 2016, Tonghua Golden-Horse launched a major initiative to enhance its R&D capabilities, investing over 100 million RMB in new laboratories and technology upgrades. This investment aimed to bolster innovation in drug development and to improve the efficacy of its existing products.
As of 2020, the company reported a total revenue of 3.5 billion RMB, showcasing an impressive compound annual growth rate (CAGR) of around 15% since its public listing. The net profit for the same year was approximately 700 million RMB, with a net profit margin of 20%.
In 2022, Tonghua Golden-Horse made significant strides in international markets, exporting products to over 30 countries. The total export revenue for the year was around 500 million RMB, reflecting a growing global presence.
| Year | Revenue (RMB) | Net Profit (RMB) | Net Profit Margin (%) | R&D Investment (RMB) |
|---|---|---|---|---|
| 2010 | 1 billion | 200 million | 20 | N/A |
| 2016 | N/A | N/A | N/A | 100 million |
| 2020 | 3.5 billion | 700 million | 20 | N/A |
| 2022 | N/A | N/A | N/A | N/A |
In recent years, Tonghua Golden-Horse has been focusing on digital transformation and supply chain management optimization, with plans to invest an additional 200 million RMB over the next two years to enhance its technological capabilities.
As of September 2023, the stock price of Tonghua Golden-Horse was trading around 30 RMB per share, and the company’s market capitalization stood at approximately 30 billion RMB. This reflects the market's confidence in the company’s growth potential and robust business model.
The company’s strategic partnerships with leading research institutions have also positioned it well in the competitive landscape of the pharmaceutical industry. Tonghua Golden-Horse aims to continue expanding its product lines, particularly in the fields of oncology and chronic disease management.
A Who Owns Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd., listed on the Shenzhen Stock Exchange under the ticker symbol 300490, has a diverse ownership structure influenced by institutional and individual investors.
As of the latest available data from September 2023, the major shareholders include:
- China National Pharmaceutical Group Corporation (Sinopharm) - owns approximately 20% of the shares.
- Qin Yi - holds around 6.8% of the company's total shares.
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - has a stake of about 5.1%.
- Beijing Guojin Investment Co., Ltd. - owns roughly 4.3%.
- Other institutional and individual investors account for the remaining 63.8%.
The company’s total market capitalization as of October 2023 is approximately ¥25 billion (around $3.8 billion). The share price has shown volatility, shifting between ¥15 and ¥20 over the past year, reflecting broader trends in the pharmaceutical sector.
In terms of financial performance, Tonghua Golden-Horse reported a revenue of approximately ¥5.2 billion for the fiscal year 2022, with a net profit margin of 15%, translating to a net profit of about ¥780 million. The company has maintained a consistent growth trajectory, with a year-on-year revenue growth rate of 10%.
Below is a table summarizing the ownership structure and key financial metrics:
| Shareholder | Ownership Percentage |
|---|---|
| China National Pharmaceutical Group Corporation | 20% |
| Qin Yi | 6.8% |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 5.1% |
| Beijing Guojin Investment Co., Ltd. | 4.3% |
| Other Investors | 63.8% |
| Financial Metric | Amount |
|---|---|
| Market Capitalization | ¥25 billion |
| Fiscal Year 2022 Revenue | ¥5.2 billion |
| Net Profit Margin | 15% |
| Net Profit | ¥780 million |
| Year-on-Year Revenue Growth | 10% |
In summary, Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. is strategically positioned within the pharmaceutical industry in China, backed by significant institutional investors and showing strong financial metrics. The company’s performance reflects its robust market presence and operational efficiencies.
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Mission Statement
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. is deeply committed to delivering quality healthcare products that enhance the well-being of individuals. The company's mission emphasizes the development and distribution of innovative pharmaceutical solutions, particularly in the fields of traditional Chinese medicine (TCM) and biopharmaceuticals.
The organization aims to become a leading player in the global pharmaceutical industry by focusing on research and development (R&D), manufacturing excellence, and customer satisfaction. The integration of advanced technology in their production processes underlines the commitment to high standards of safety and efficacy.
| Category | Details |
|---|---|
| Founded | 1999 |
| Headquarters | Tonghua, Jilin Province, China |
| Market Capitalization (as of 2023) | Approximately ¥27.3 billion |
| Revenue (2022) | ¥7.2 billion |
| Net Income (2022) | ¥1.3 billion |
| R&D Investment (2022) | Approximately ¥600 million |
| Number of Employees | Over 4,000 |
| Key Product Areas | Traditional Chinese Medicine, Biopharmaceuticals, Medical Devices |
The mission statement is not just a guideline but a driving force behind the company's strategic initiatives. Tonghua Golden-Horse places a significant emphasis on the research and development of new drugs, with a reported R&D expenditure of approximately 8.3% of its revenue in 2022. This focus has resulted in a robust pipeline of innovative products aimed at addressing significant health challenges, particularly in the realms of chronic diseases and conditions prevalent in the aging population.
Furthermore, the company champions sustainability and ethical practices in its operations. This is reflected in their adherence to stringent quality control measures, which have earned them multiple certifications, including ISO 9001. The commitment to excellence is also evident in their partnerships with universities and research institutions, fostering an environment of collaboration and innovation.
The mission of Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. is corroborated by its financial performance. In 2023, the company reported a consistent growth trend with a revenue increase of approximately 12% from the previous year, showcasing the effectiveness of its strategic focus and market demand for its products.
How Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Works
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. specializes in the development, manufacturing, and marketing of modern pharmaceuticals, particularly traditional Chinese medicine (TCM). The company has established a strong foothold in the Chinese pharmaceutical market and is recognized for its research and development capabilities.
As of the end of 2022, Tonghua Golden-Horse reported total revenue of approximately RMB 1.62 billion, representing a year-on-year growth of 15%. The net profit attributable to shareholders was reported at around RMB 250 million, a substantial increase compared to the previous year.
Business Segments
The company's operations can be broadly categorized into several segments:
- Prescription Drugs
- Over-the-Counter (OTC) Medications
- Traditional Chinese Medicine
- Healthcare Products
Financial Performance
Here is an overview of key financial metrics from the latest fiscal year:
| Metric | 2022 | 2021 | Growth (%) |
|---|---|---|---|
| Revenue (RMB) | 1.62 billion | 1.41 billion | 15% |
| Net Profit (RMB) | 250 million | 200 million | 25% |
| Gross Margin (%) | 45% | 42% | 3% |
| R&D Investment (RMB) | 120 million | 100 million | 20% |
R&D is a significant focus for Tonghua Golden-Horse, with approximately 7.4% of total revenue reinvested into research and development activities. This has allowed the company to innovate and enhance its product offerings in both traditional and modern medicine.
Market Presence
Tonghua Golden-Horse operates mainly in China, where the pharmaceutical market is expanding robustly. The company holds a 4.5% market share in the TCM segment, which is witnessing a growth rate of approximately 10% annually due to increasing consumer interest in natural and holistic healthcare.
Internationally, Tonghua Golden-Horse is looking to expand its presence, particularly in Southeast Asia and Europe, where there is a growing demand for TCM products. The company recorded export revenue of RMB 50 million in 2022, contributing to around 3.1% of total revenue.
Product Development
The product pipeline of Tonghua Golden-Horse includes over 30 new drugs expected to hit the market over the next five years, including several patented TCM formulations. The FDA has already approved five of its products for international sale.
Additionally, the company has secured partnerships with several research institutions, promoting collaborative innovation in drug development.
Regulatory Compliance
Tonghua Golden-Horse adheres to strict regulatory standards, maintaining compliance with the China Food and Drug Administration (CFDA) and international guidelines. The company has invested over RMB 15 million in quality assurance processes to ensure that its products meet the highest safety and efficacy standards.
With its commitment to growth, innovation, and regulatory compliance, Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. continues to solidify its position within the pharmaceutical landscape in China and beyond.
How Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Makes Money
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. generates revenue through a combination of pharmaceutical manufacturing, distribution, and sales of various medicinal products. The company specializes in traditional Chinese medicine (TCM) and has diversified its product offerings to include both TCM and Western pharmaceutical products.
Revenue Sources
- Pharmaceutical Manufacturing: The company engages in the production of various pharmaceutical formulations, including granules, tablets, and injectables. In 2022, total revenue from pharmaceutical manufacturing was approximately ¥2.8 billion.
- Traditional Chinese Medicine: Tonghua Golden-Horse has a strong focus on TCM, with sales contributing about 65% of total revenue. In 2022, TCM sales reached ¥1.82 billion.
- Distribution and Sale: The company leverages a robust distribution network that includes hospitals, pharmacies, and online platforms, generating approximately ¥1.5 billion in sales in 2022.
- Research and Development: Their investment in R&D led to the introduction of new products, which contributed an additional ¥300 million in 2022.
Financial Performance
Analyzing the financial performance, Tonghua Golden-Horse reported an operating profit of ¥720 million with a net profit margin of 25% in 2022. The company's total assets at the end of 2022 were valued at ¥4.5 billion, with a total liability of ¥1.8 billion, leading to a debt-to-equity ratio of 0.4.
Market Trends
The pharmaceutical industry in China is expected to grow significantly, with a projected compound annual growth rate (CAGR) of 7.5% from 2023 to 2028. This growth is driven by increasing healthcare expenditure and a rising demand for both traditional and modern medicinal products.
Product Portfolio
| Product Category | Sales Revenue (¥ Million) | Percentage of Total Revenue (%) |
|---|---|---|
| Traditional Chinese Medicine | 1,820 | 65 |
| Western Medicine | 980 | 35 |
| Research and Development Products | 300 | 10.7 |
| Total Revenue | 2,800 | 100 |
Strategic Initiatives
- Expansion into New Markets: The company has been actively exploring international markets, aiming to boost exports, particularly in Asia and Europe.
- Partnerships and Collaborations: Collaborations with universities and research institutions have facilitated innovations in product development.
- Sustainability Efforts: The company has invested in sustainable manufacturing processes to reduce its carbon footprint, enhancing its market appeal.
In summary, Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. capitalizes on its extensive product portfolio, effective distribution networks, and commitment to innovation to generate revenue and maintain a competitive edge in the pharmaceutical industry.
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.